keyword
https://read.qxmd.com/read/35931925/curbing-covid-19-vaccine-hesitancy-from-a-dermatological-standpoint-analysis-of-cutaneous-reactions-in-the-vaccine-adverse-event-reporting-system-vaers-database
#21
JOURNAL ARTICLE
Julianne M Falotico, Amar D Desai, Asghar Shah, Jose W Ricardo, Shari R Lipner
OBJECTIVES: Adverse reactions to the COVID-19 vaccines have been of interest since their emergency authorization. Cutaneous manifestations of the vaccines are not well studied. We aimed to characterize cutaneous reactions to the Moderna (mRNA-1273) and the Pfizer-BioNTech (BNT162b2) COVID-19 vaccines on a large, national scale. METHODS: The Vaccine Adverse Event Reporting System was filtered for cutaneous and hair and nail reactions to the COVID-19 vaccines. Patient demographics and past medical histories, vaccine manufacturer and dosing, symptom timing, reaction location, and patient outcomes were extracted from each report...
August 5, 2022: American Journal of Clinical Dermatology
https://read.qxmd.com/read/35740660/contribution-of-the-skin-gut-axis-to-immune-related-adverse-events-with-multi-system-involvement
#22
JOURNAL ARTICLE
Alyce M Kuo, Lukas Kraehenbuehl, Stephanie King, Donald Y M Leung, Elena Goleva, Andrea P Moy, Mario E Lacouture, Neil J Shah, David M Faleck
Immune-related adverse events (irAEs) frequently complicate treatment with immune checkpoint blockade (ICB) targeting CTLA-4, PD-1, and PD-L1, which are commonly used to treat solid and hematologic malignancies. The skin and gastrointestinal (GI) tract are most frequently affected by irAEs. While extensive efforts to further characterize organ-specific adverse events have contributed to the understanding and management of individual toxicities, investigations into the relationship between multi-organ toxicities have been limited...
June 17, 2022: Cancers
https://read.qxmd.com/read/35138364/human-polyomavirus-9-an-emerging-cutaneous-and-pulmonary-pathogen-in-solid-organ-transplant-recipients
#23
JOURNAL ARTICLE
Nischay Mishra, James Ng, Mark A Strom, Komal Jain, Riddhi Thakkar, Shreyas Joshi, Marcus Pereira, Lori Shah, Marc E Grossman, Michael J Lee, Simona De Michele, David N Silvers, Phyllis L Faust, W Ian Lipkin, Stephanie M Gallitano
IMPORTANCE: We describe the first report to our knowledge of cutaneous and systemic pathogenicity of human polyomavirus 9 in solid organ transplant recipients. OBJECTIVE: Three solid organ transplant recipients developed a widespread, progressive, violaceous, and hyperkeratotic skin eruption. All died from pulmonary and multiorgan failure around 1 year from onset of the rash. Routine clinical diagnostic testing could not identify any causative agent; therefore, samples and autopsies were investigated for novel pathogens using high-throughput sequencing...
March 1, 2022: JAMA Dermatology
https://read.qxmd.com/read/34992070/safety-and-efficacy-of-combination-maintenance-therapy-with-ixazomib-and-lenalidomide-in-patients-with-posttransplant-myeloma
#24
JOURNAL ARTICLE
Krina K Patel, Jatin J Shah, Lei Feng, Hans C Lee, Elisabet M Manasanch, Jasper Olsem, Ashley Morphey, Xiao Jiao Huo, Sheeba K Thomas, Qaiser Bashir, Muzaffar H Qazilbash, Donna M Weber, Robert Z Orlowski
PURPOSE: In this study, the addition of ixazomib to lenalidomide maintenance post-autologous stem cell transplant (ASCT) in 64 patients with newly diagnosed multiple myeloma was evaluated on the basis of the observed benefit of lenalidomide-only maintenance in prior studies. PATIENTS AND METHODS: Patients were started on maintenance therapy with lenalidomide and ixazomib within 60-180 days of stem cell infusion. RESULTS: Response rates deepened over time from baseline post-ASCT for 39 patients...
April 1, 2022: Clinical Cancer Research
https://read.qxmd.com/read/34902455/durable-polymer-drug-eluting-stent-induced-kounis-syndrome-and-eosinophilia-requiring-long-term-immunosuppression
#25
JOURNAL ARTICLE
Thomas Boucher, Aman M Shah, Hayder Hashim, Elina Jerschow, Anna E Bortnick
There are no reports of systemic eosinophilic reactions to durable polymer coated drug eluting stents (DP-DES) and a consensus statement indicates that these devices should be considered in nickel allergy. We present a case of in-stent thrombosis, eosinophilia, and rash consistent with allergic myocardial infarction, a presentation of Kounis syndrome, in the context of metal allergy to DP-DES requiring long-term immunosuppression.
March 2022: Canadian Journal of Cardiology
https://read.qxmd.com/read/34446535/predictors-of-invasive-herpes-simplex-virus-infection-in-young-infants
#26
JOURNAL ARTICLE
Andrea T Cruz, Lise E Nigrovic, Jianling Xie, Prashant Mahajan, Joanna E Thomson, Pamela J Okada, Neil G Uspal, Rakesh D Mistry, Aris Garro, David Schnadower, Dina M Kulik, Sarah J Curtis, Aaron S Miller, Alesia H Fleming, Todd W Lyons, Fran Balamuth, Joseph L Arms, Jeffrey Louie, Paul L Aronson, Amy D Thompson, Paul T Ishimine, Suzanne M Schmidt, Christopher M Pruitt, Samir S Shah, Kendra L Grether-Jones, Stuart A Bradin, Stephen B Freedman
OBJECTIVES: To identify independent predictors of and derive a risk score for invasive herpes simplex virus (HSV) infection. METHODS: In this 23-center nested case-control study, we matched 149 infants with HSV to 1340 controls; all were ≤60 days old and had cerebrospinal fluid obtained within 24 hours of presentation or had HSV detected. The primary and secondary outcomes were invasive (disseminated or central nervous system) or any HSV infection, respectively...
September 2021: Pediatrics
https://read.qxmd.com/read/34342089/clinical-effects-and-safety-of-ferric-carboxymaltose-in-pregnancy-an-indian-real-life-experience
#27
JOURNAL ARTICLE
Sanjay A Gupte, Gayatri Venkataraman, Aarti S Shah, Aparna S Mudholkar, Shweta M Jangam
BACKGROUND: There is limited clinical evidence of ferric carboxymaltose injection (FCM) usage in Indian pregnant women. We assessed the efficacy and safety of FCM in Indian pregnant women with moderate-to-severe anemia. METHODS: Single-center, retrospective, observational data collection was conducted at a tertiary care research institute. Data of pregnant women with anemia who received FCM in their second and third trimester was retrieved and analyzed for hematological parameters at baseline and at 4 ± 2 weeks...
August 2, 2021: Journal of Obstetrics and Gynaecology Research
https://read.qxmd.com/read/34170745/phase-ii-trial-of-pembrolizumab-plus-gemcitabine-vinorelbine-and-liposomal-doxorubicin-as-second-line-therapy-for-relapsed-or-refractory-classical-hodgkin-lymphoma
#28
MULTICENTER STUDY
Alison J Moskowitz, Gunjan Shah, Heiko Schöder, Nivetha Ganesan, Esther Drill, Helen Hancock, Theresa Davey, Leslie Perez, Sunyoung Ryu, Samia Sohail, Alayna Santarosa, Natasha Galasso, Rachel Neuman, Brielle Liotta, William Blouin, Anita Kumar, Oscar Lahoud, Connie L Batlevi, Paul Hamlin, David J Straus, Ildefonso Rodriguez-Rivera, Colette Owens, Philip Caron, Andrew M Intlekofer, Audrey Hamilton, Steven M Horwitz, Lorenzo Falchi, Erel Joffe, William Johnson, Christina Lee, M Lia Palomba, Ariela Noy, Matthew J Matasar, Georgios Pongas, Gilles Salles, Santosha Vardhana, Beatriz Wills Sanin, Gottfried von Keudell, Joachim Yahalom, Ahmet Dogan, Andrew D Zelenetz, Craig H Moskowitz
PURPOSE: We conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) (ClinicalTrials.gov identifier: NCT03618550). METHODS: Transplant eligible patients with rel/ref cHL following first-line therapy were treated with two to four cycles of pembrolizumab (200 mg intravenous [IV], day 1), gemcitabine (1,000 mg/m2 IV, days 1 and 8), vinorelbine (20 mg/m2 IV, days 1 and 8), and liposomal doxorubicin (15 mg/m2 , days 1 and 8), given on 21-day cycles...
October 1, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33986606/dermatological-and-genital-manifestations-of-lyme-disease-including-morgellons-disease
#29
Marianne J Middelveen, John S Haggblad, Julie Lewis, Gilles A Robichaud, Roberto M Martinez, Jyotsna S Shah, Iris Du Cruz, Melissa C Fesler, Raphael B Stricker
Although the erythema migrans (EM) skin rash is traditionally considered a hallmark of Lyme disease, other dermatological manifestations of the tickborne disease are less well known. We describe a 49-year-old woman with erosive genital ulcerations, secondary EM rashes and jagged skin lesions associated with Lyme disease. The skin rashes exhibited fibers characteristic of Morgellons disease. Molecular testing confirmed the presence of Borrelia DNA in both vaginal culture and serum specimens. In further studies on a secondary EM lesion containing filaments, Gömöri trichrome staining revealed the presence of collagen in the filaments, while Dieterle and anti- Borrelia immunostaining revealed intracellular and extracellular Borrelia organisms...
2021: Clinical, Cosmetic and Investigational Dermatology
https://read.qxmd.com/read/33946504/efficacy-and-safety-of-bevacizumab-plus-erlotinib-in-patients-with-renal-medullary-carcinoma
#30
JOURNAL ARTICLE
Andrew J Wiele, Devaki Shilpa Surasi, Priya Rao, Kanishka Sircar, Xiaoping Su, Tharakeswara K Bathala, Amishi Y Shah, Eric Jonasch, Vince D Cataldo, Giannicola Genovese, Jose A Karam, Christopher G Wood, Nizar M Tannir, Pavlos Msaouel
PURPOSE: To assess the efficacy and safety of bevacizumab plus erlotinib in patients with RMC. METHODS: We retrospectively reviewed the records of patients with RMC treated with bevacizumab plus erlotinib at our institution. RESULTS: Ten patients were included in the study. Two patients achieved a partial response (20%) and seven patients achieved stable disease (70%). Tumor burden was reduced in seven patients (70%) in total, and in three out of five patients (60%) that had received three or more prior therapies...
April 30, 2021: Cancers
https://read.qxmd.com/read/33856405/safety-and-effectiveness-of-weekly-carfilzomib-lenalidomide-dexamethasone-and-daratumumab-combination-therapy-for-patients-with-newly-diagnosed-multiple-myeloma-the-manhattan-nonrandomized-clinical-trial
#31
JOURNAL ARTICLE
Ola Landgren, Malin Hultcrantz, Benjamin Diamond, Alexander M Lesokhin, Sham Mailankody, Hani Hassoun, Carlyn Tan, Urvi A Shah, Sydney X Lu, Meghan Salcedo, Kelly Werner, Jenna Rispoli, Julia Caple, Allison Sams, Dennis Verducci, Katie Jones, Isabel Concepcion, Amanda Ciardello, Aisara Chansakul, Julia Schlossman, Elizabet Tavitian, Tala Shekarkhand, Angela Harrison, Casey Piacentini, Even H Rustad, Venkata Yellapantula, Kylee Maclaughlan, Francesco Maura, Heather J Landau, Michael Scordo, David J Chung, Gunjan Shah, Oscar B Lahoud, Katie Thoren, Kazunori Murata, Lakshmi Ramanathan, Maria E Arcila, Caleb Ho, Mikhail Roshal, Ahmet Dogan, Andriy Derkach, Sergio A Giralt, Neha Korde
IMPORTANCE: Recently, the benefit of adding daratumumab to the proteasome inhibitor-based, 3-drug combination of bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma who underwent high-dose melphalan chemotherapy and autologous hemopoietic cell transplant was assessed. Here, we examine the addition of daratumumab to the second-generation proteasome inhibitor-based, 3-drug combination of carfilzomib, lenalidomide, and dexamethasone. OBJECTIVE: To assess the safety and effectiveness of carfilzomib-lenalidomide-dexamethasone-daratumumab combination therapy for patients with newly diagnosed multiple myeloma, in the absence of high-dose melphalan chemotherapy and autologous hemopoietic cell transplant...
June 1, 2021: JAMA Oncology
https://read.qxmd.com/read/33747934/case-report-enfortumab-vedotin-for-metastatic-urothelial-carcinoma-a-case-series-on-the-clinical-and-histopathologic-spectrum-of-adverse-cutaneous-reactions-from-fatal-stevens-johnson-syndrome-toxic-epidermal-necrolysis-to-dermal-hypersensitivity-reaction
#32
Paul V Viscuse, Mario L Marques-Piubelli, Meghan M Heberton, Edwin Roger Parra, Amishi Y Shah, Arlene Siefker-Radtke, Jianjun Gao, Sangeeta Goswami, Doina Ivan, Jonathan L Curry, Matthew T Campbell
Enfortumab vedotin is a Nectin-4 directed antibody-drug conjugate approved in metastatic urothelial carcinoma following progression on a platinum-containing chemotherapy and immune checkpoint blockade. On-target dermatologic toxicity may occur from Nectin-4 expression in the skin. We highlight a case of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis following enfortumab infusions that was ultimately fatal. The second case describes an erythema multiforme-like rash with interface dermatitis related to enfortumab...
2021: Frontiers in Oncology
https://read.qxmd.com/read/33664147/draft-genome-sequences-of-seven-vibrio-cholerae-isolates-from-adult-patients-in-qatar
#33
JOURNAL ARTICLE
Ameena Al Malki, Kyle D Brumfield, Clement K M Tsui, Anjana Anand, Shah M Rashed, Emad Ibrahim, Hamad Al Shamari, Anwar Huq, Rita R Colwell, Rashmi Fotedar
We report the draft genome sequences of seven Vibrio cholerae isolates from patients. Four isolates were profiled as multilocus sequence type 69, serogroup O1, a subset of seventh-pandemic El Tor clonal isolates. Presented here are genome assemblies and evidence for major pathogenicity islands, virulence factors, and antimicrobial resistance genes.
March 4, 2021: Microbiology Resource Announcements
https://read.qxmd.com/read/33617476/no-evidence-of-o-nyong-nyong-viremia-among-children-with-febrile-illness-in-kenya-2015-2018
#34
JOURNAL ARTICLE
Melisa M Shah, Bryson A Ndenga, Francis M Mutuku, Victoria Okuta, Charles O Ronga, Philip K Chebii, Priscilla Maina, Zainab Jembe, Malaya K Sahoo, ChunHong Huang, Jenna Weber, Benjamin A Pinsky, Angelle Desiree LaBeaud
O'nyong-nyong virus (ONNV) is a little-known arbovirus causing intermittent, yet explosive, outbreaks in Africa. It is closely related to chikungunya virus, an emerging infectious disease. O'nyong-nyong virus causes a self-limited illness characterized by bilateral polyarthritis, rash, low-grade fever, and lymphadenopathy. In 1959, an extensive outbreak of ONNV occurred in East Africa, and decades later, another large outbreak was documented in Uganda in 1996. Limited evidence for interepidemic transmission is available, although serologic studies indicate a high prevalence of exposure...
February 22, 2021: American Journal of Tropical Medicine and Hygiene
https://read.qxmd.com/read/33251369/epidemiological-study-of-human-rabies-cases-in-bangladesh-through-verbal-autopsy
#35
JOURNAL ARTICLE
Md Sohel Rana, Umme Ruman Siddiqi, Sumon Ghosh, Afsana Akter Jahan, Md Kamrul Islam, Md Rashed Ali Shah, Sayed Mohammed Ullah, S M Emran Ali, Be-Nazir Ahmed, Abul Khair Mohammad Shamsuzzaman
Identification of risk factors is crucial to find ways to reduce rabies deaths. We investigated the hospital records of rabies deceased through contact tracing of the relatives of the victims using enhanced verbal autopsies (VA) to identify why the people had to die from rabies in recent years in Bangladesh. Patients whose deaths were confirmed by physicians based on the history of animal exposure and clinical signs were taken into account for VA. Socio-demographic profile of the deceased, animal exposure, nature of the wound, and history of post-exposure prophylaxis (PEP) data were obtained and analysed...
November 2020: Heliyon
https://read.qxmd.com/read/33108647/granulomatous-cutaneous-drug-eruptions-a-systematic-review
#36
Nidhi Shah, Monica Shah, Aaron M Drucker, Neil H Shear, Michael Ziv, Roni P Dodiuk-Gad
BACKGROUND: Granulomatous drug eruptions are rare entities, where granuloma formation occurs as an attempt to contain an exogenous or endogenous inciting agent. Granulomatous drug eruptions may be localized to the skin or may include major systemic involvement, and their characteristics depend both on the properties of the causative irritant and host factors. Because of the overlapping features amongst noninfectious granulomatous diseases, granulomatous drug eruptions are challenging to diagnose and distinguish both histologically and clinically...
January 2021: American Journal of Clinical Dermatology
https://read.qxmd.com/read/33046621/safety-and-efficacy-of-amg-820-an-anti-colony-stimulating-factor-1-receptor-antibody-in-combination-with-pembrolizumab-in-adults-with-advanced-solid-tumors
#37
JOURNAL ARTICLE
Albiruni Ra Razak, James M Cleary, Victor Moreno, Michael Boyer, Emiliano Calvo Aller, William Edenfield, Jeanne Tie, R Donald Harvey, Annemie Rutten, Manish A Shah, Anthony J Olszanski, Dirk Jäger, Nehal Lakhani, David P Ryan, Erik Rasmussen, Gloria Juan, Hansen Wong, Neelesh Soman, Marie-Anne Damiette Smit, Dirk Nagorsen, Kyriakos P Papadopoulos
BACKGROUND: To determine the safety and efficacy of the anti-colony-stimulating factor 1 receptor (anti-CSF1R) monoclonal antibody AMG 820 in combination with pembrolizumab in patients with select solid tumors. PATIENTS AND METHODS: Patients had advanced, refractory mismatch repair-proficient colorectal cancer, pancreatic cancer, or non-small cell lung cancer (NSCLC) with low (<50%) programmed cell death-ligand 1 (PD-L1) expression and were naïve to anti-programmed cell death-1 (PD-1)/PD-L1 or had relapsed/refractory NSCLC after anti-PD-1/PD-L1 treatment with low or high (≥50%) PD-L1 expression; all were anti-CSF1/CSF1R naïve...
October 2020: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/32864625/alterations-in-pten-and-esr1-promote-clinical-resistance-to-alpelisib-plus-aromatase-inhibitors
#38
JOURNAL ARTICLE
Pedram Razavi, Maura N Dickler, Payal D Shah, Weiyi Toy, David N Brown, Helen H Won, Bob T Li, Ronglai Shen, Neil Vasan, Shanu Modi, Komal Jhaveri, Betty Ann Caravella, Sujata Patil, Pier Selenica, Stephen Zamora, Aimee M Cowan, Elizabeth Comen, Andy Singh, Anne Covey, Michael F Berger, Clifford A Hudis, Larry Norton, Rebecca J Nagy, Justin I Odegaard, Richard B Lanman, David B Solit, Mark E Robson, Mario E Lacouture, Edi Brogi, Jorge S Reis-Filho, Mary Ellen Moynahan, Maurizio Scaltriti, Sarat Chandarlapaty
Alpelisib is a selective inhibitor of PI3Kα, shown to improve outcomes for PIK3CA mutant, hormone receptor positive (HR+) metastatic breast cancers (MBC) when combined with antiestrogen therapy. To uncover mechanisms of resistance, we conducted a detailed, longitudinal analysis of tumor and plasma circulating tumor DNA among such patients from a phase I/II trial combining alpelisib with an aromatase inhibitor (AI) (NCT01870505). The trial's primary objective was to establish safety with maculopapular rash emerging as the most common grade 3 adverse event (33%)...
April 2020: Nature Cancer
https://read.qxmd.com/read/32785212/atypical-reactivation-of-varicella-zoster-virus-associated-with-pancreatitis-in-a-heart-transplant-patient
#39
JOURNAL ARTICLE
Christine Shieh, Ashley Barnes, Drew M Johnson, Ilya M Danelich, Preethi Pirlamarla, Rene Alvarez, Howard Massey, Mahek Shah
BACKGROUND Acute pancreatitis is rare following solid organ transplantation but is associated with high mortality. It has been most commonly reported following renal transplant but can occur with other solid organ transplantations. CASE REPORT A 46-year-old male who had an orthotopic heart transplant 6 months ago presented with a 3-week history of abdominal pain. The patient described it as intermittent, sharp, and stabbing, originating in the periumbilical area and radiating to the back. His lipase was elevated at 232 U/L...
August 12, 2020: American Journal of Case Reports
https://read.qxmd.com/read/32271799/a-comparative-analysis-of-drinking-water-employing-metagenomics
#40
COMPARATIVE STUDY
Kyle D Brumfield, Nur A Hasan, Menu B Leddy, Joseph A Cotruvo, Shah M Rashed, Rita R Colwell, Anwar Huq
The microbiological content of drinking water traditionally is determined by employing culture-dependent methods that are unable to detect all microorganisms, especially those that are not culturable. High-throughput sequencing now makes it possible to determine the microbiome of drinking water. Thus, the natural microbiota of water and water distribution systems can now be determined more accurately and analyzed in significantly greater detail, providing comprehensive understanding of the microbial community of drinking water applicable to public health...
2020: PloS One
keyword
keyword
108293
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.